EGFR and central nervous system cancer: In the 24 h vs. 24 h ST trial contrast KEGG pathway analysis (Supplementary Table 5a) with more balanced hypo/hypermethylation ratio: (1) ErbB signaling, (2) Non-small cell lung cancer, (3) axon guidance, (4) proteoglycans in cancer, and (5) glioma (Supplementary Tables 5b–f).